List of Namenda Xr drug patents
Namenda Xr is owned by Allergan.
Namenda Xr contains Memantine Hydrochloride.
Namenda Xr has a total of 2 drug patents out of which 0 drug patents have expired.
Namenda Xr was authorised for market use on 21 June, 2010.
Namenda Xr is available in capsule, extended release;oral dosage forms.
Namenda Xr can be used as treatment of moderate to severe dementia of the alzheimer's type.
The generics of Namenda Xr are possible to be released after 24 September, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8039009 | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(6 years from now) | |
|
US8039009
(Pediatric) | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(6 years from now) | |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 June, 2010
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
NAMENDA XR family patents
11
United States
1
Brazil
1
Australia
1
Canada
1
Mexico
1
EA
1
China
1
Japan
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic